

ACN 153 273 735 / ASX: MX1

MICRO-X

SHARECAFE INVESTOR WEBINAR

10th September 2021

Peter Rowland
Managing Director & CEO



IMPORTANT NOTICE DISCLAIMER



SCOPE & LIMITATIONS

This Presentation has been prepared by Micro-X Limited (**Micro-X** or the **Company**) (ASX.MX1). The Presentation is a summary only and does not contain all the information about the Company's assets and liabilities, financial position and performance, profits and losses and prospects. This material in this Presentation may be supplemented with an oral presentation and/or other more detailed documents and should not be taken out of context. Although the information contained herein is based upon generally available information and has been obtained from third-party sources believed to be reliable, the Company does not guarantee its accuracy, and such information may be incomplete or condensed. The Company also refers to its filings made with the ASX Limited and the Australian Securities & Investments Commission.

FORWARD LOOKING INFORMATION

This Presentation contains forward looking and other subjective information. Such expectations, estimates, projections and information are not a guarantee of future performance and involve unknown risks and uncertainties. Actual results and developments will almost certainly differ from those expressed or implied and recipients of this Presentation should make their own assessment of the expectations, estimates, projections and the relevant assumptions and calculations upon which the opinions, estimates and projections are based. No representation or warranty, express or implied, is given as to the accuracy or completeness of the information or opinions contained in this Presentation and no liability whatsoever is accepted by the Company, or its directors, members, officers, employees, agents or advisers for any use or, or reliance placed upon, such information or opinions.

NOT AN OFFER FOR SECURITIES

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any shares nor does it constitute financial product or investment advice nor take into account your investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this Presentation but must make its own assessment of the Company and conduct its own investigations and analysis. Before making an investment in the Company, a prospective investor should consider whether such an investment is appropriate to their particular investment objectives and financial situation and seek appropriate advice, including legal, taxation and financial advice appropriate to their jurisdiction and circumstances.

UNITED STATES

The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the **Securities Act**), or under the securities laws of any state or other jurisdiction of the

United States. Accordingly, the Company's securities may not be offered or sold, directly or indirectly, within the United States or to, or for the account of benefit of, U.S. Persons (as defined in Regulation S under the Securities Act as amended). This Presentation may not be distributed within the United States or to any person in the United States

OTHER JURISDICTIONS

This Presentation may only be accessed in other jurisdictions where it is legal to do so.

MINIATURISING X-RAY

First Mover in Next Generation X-ray for Global Health and Security Markets

MICRO-X

Platform technology in cold cathode x-ray

- X-ray products with significant reduction in size, weight and power
- **Patented technology** – platform for health and new security applications
- **First to market** with proven cold cathode medical x-ray product

25kg




Comparison

Conventional x-ray tube and Micro-X x-ray tube

1.5kg

OUR STRATEGY

To Monetise Our 'First Mover' Advantage



MICRO-X

OUR GOAL

Four global production lines

- common technology platforms
- high-margin
- operating within five years

OUR 4 PRODUCT LINES

Mobile DR

Bedside imaging – Medical, Military, Vet

IED X-ray Camera

Counter terrorist bomb assessment

Airport Checkpoint

Self-service airport security

Brain CT

In-ambulance stroke imaging

MOBILE DIGITAL RADIOLOGY

Extending Bedside Imaging with Lightweight and Ultra-mobility

\$3.6m

Sales FY21

4

New Distributors Signed

2021

Rover Mark II Launched

THE PRODUCT RANGE


OEM Products – ‘Carestream DRX-Revolution Nano’

- First sold 2018 – now operating in 20+ countries
- Other, non exclusive OEM partnerships in development

Micro-X ‘Rover’ – wholly Micro-X branded and controlled imaging solution for:

- **Medical** hospitals & temporary facilities
- Ruggedised for deployed **military** hospitals and humanitarian aid
- **Veterinary** applications in small-animal hospitals and specialist clinics

MICRO-X



IED X-RAY CAMERA

Next Generation Security Device to Save Lives

\$1.8b

Addressable market

Prototype


Dec 2021

2022

Target Launch

- ✖ X-ray camera takes images like a camera - **one sided viewing** without separate detector
- ✖ Bomb disposal technicians face life threatening situation when 'over the target' placing a conventional x-ray detector
- ✖ Small size and weight – easily carried by robots
- ✖ Australian Defence Force **proof of concept imaging completed**
- ✖ **Military and FBI / bomb disposal interest**
- ✖ **No competition = higher gross margins**

MICRO-X



First public showing of IED X-Ray Camera at Army Robotics Conference in April 2021,
IED X-Ray Camera being held by T7 Robot

AIRPORT SELF-SERVICE CHECKPOINT

US Dept. of Homeland Security – Two Contracts Totalling US\$4m

US\$24b

Addressable market

US\$4m

Two contracts for US
Dept of Homeland
Security

- ✦ A blend of backscatter and transmission x-ray to provide **three-dimensional imaging of carry on luggage**
- ✦ Integrated body scanner and passport reader
- ✦ Based on work Micro-X undertook in 2 contracts won from UK's Department for Transport
- ✦ Concept reimagines the future of airport checkpoints based on self-service model
- ✦ Addressable global market ~ US\$24B
TSA alone US\$8B market opportunity

MICRO-X



Above: Illustration of Future Airport Checkpoint Portal

BRAIN CT IMAGING FOR STROKE DIAGNOSIS

Pre-Hospital Diagnosis & Treatment in Ambulance

US\$5b

Addressable market

\$8m

Australian Stroke Alliance
– MRFF funding

PARTNERS



FUJIFILM



- ✦ CT imaging with no moving parts – small enough and affordable to be fitted to every ambulance
- ✦ Early stroke diagnosis allows treatment in a road or air ambulance – improved patient outcomes within the ‘Golden Hour’
- ✦ Curved detector will be the first of its kind – provided in collaboration with **Fujifilm**
- ✦ **\$8m funding** under Second Phase of Australian Stroke Alliance Project – Medical Research Future Fund
- ✦ **Potential to be a game changer in modern stroke management with addressable market ~\$5b**

MICRO-X



Above: Illustration of curved CT scanner in ambulance setting

SIGNIFICANT MARKETS ACROSS FOUR PRODUCTION LINES

Sequenced Product Rollout as CNT Manufacturing Expands



Mobile DR Range

First Sales
2018

Addressable Market
US\$500m pa*



IED X-Ray Camera

First Sales
2022*

Addressable Market
US\$1.8b



Airport Checkpoint

First Sales
2023*

Addressable Market
USA: US\$8b
RoW: US\$16b



Brain CT Scanner

First Sales
2026*

Addressable Market
US\$5b

* Pre COVID-19 levels

* These dates are estimates and may vary

ESTABLISHED CAPABILITIES

Key Disciplines – Engineering Design, Development and Manufacturing

MICRO-X



MILESTONES & ACHIEVEMENTS

Initiatives to Deliver Commercial Outcomes for all Stakeholders

MICRO-X

CY 2021

First IED X-Ray Camera Demonstration

Grow Micro-X Rover Paths to Market – US, EMEA

In-sourced Generator Tested

Launch Rover Veterinary

Rover Mk II – Second Generation Launched

Airport Security Contracts Signed

Brain CT Scanner Contract Signed

BEYOND

IED X-Ray Camera Prototype

Increased Mobile DR Sales

Scaling X-Ray Tube Manufacturing

IED X-Ray Camera Commercialisation

Brain CT Scanner Prototype

Airport Security Scanner Prototype

Airport Security Portal Prototype

ACN 153 273 735 / ASX: MX1

MICRO-X

THANK YOU

Peter Rowland
Managing Director & CEO



EXPERIENCED LEADERSHIP

Technical and Commercial Expertise to Support Our Objectives

MICRO-X



Peter Rowland
Managing Director & CEO

- Over 30 years' engineering and management in medical device & and aerospace industries
- Previously BAE Systems, Ellex Medical and Biolase Technology (NASDAQ)



David Knox
Non-Executive Chairman

- Extensive international business experience delivering large energy projects
- Formerly CEO of Santos and Australian Naval Infrastructure
- Chair of Snowy Hydro, Director of CSIRO




Patrick O'Brien
Non-Executive Director

- Over 25 years' business and finance experience in UK, Asia and Australia
- Former Executive Director at Macquarie Group; McKinsey; and Minter Ellison



Yasmin King
Non-Executive Director

- Extensive experience in business, negotiation & procurement and Government
- Currently CEO of Skills IQ, formerly Associate Commissioner of ACCC
- Director of the Australian Healthcare and Hospitals Association



Dr Alexander Gosling, AM
Non-Executive Director

- Over 40 years' business, technology and R&D experience
- A founding Director at Invetech (Vision Systems); strategy for Capstone



Jim McDowell
Non-Executive Director


- Extensive experience in Defence and Aerospace industries
- Current CEO of Nova Group
- Former Chief Executive of the Department of Premier for South Australia

CORPORATE SNAPSHOT

Growth Stage Company with Institutional Support

MICRO-X

MX1 - Share Trading (1 September 2020 to 8 September 2021)



Share & Trading Statistics (Closing Price on 8 September 2021)

Share Price	\$0.295 per share
Total Shares On Issue	459.7 million
Options Issued	2.5 million
Market Cap	~\$135.6m

Key Financials & Shareholders

Cash	~\$30.1m (30 June 2021) – Debt free
Institutions	~40.0% Perennial (13.5%), Regal (8.9%), Thorney (5.7%), AusSuper (5.2%)
Board & Related Parties	~ 4.8%